Home Cart Sign in  
Chemical Structure| 929095-18-1 Chemical Structure| 929095-18-1

Structure of GSK461364
CAS No.: 929095-18-1

Chemical Structure| 929095-18-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.

Synonyms: GSK461364A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK461364

CAS No. :929095-18-1
Formula : C27H28F3N5O2S
M.W : 543.60
SMILES Code : O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C3)S1)N
Synonyms :
GSK461364A
MDL No. :MFCD12755419
InChI Key :ZHJGWYRLJUCMRT-QGZVFWFLSA-N
Pubchem ID :15983966

Safety of GSK461364

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PLK1

    PLK1, Ki:2.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
NSCLC cell lines 1 μM 72 hours To determine the sensitivity of NSCLC cell lines to GSK461364, results showed varying sensitivity across different cell lines PMC4818738
Huh7 cells 0-50 nM 72 hours GSK461364 showed potent anti-tumor activity against Huh7 cells with an IC50 value of 3.2 nM PMC7459198
HepG2 cells 0-50 nM 72 hours GSK461364 showed weaker anti-tumor activity against HepG2 cells with an IC50 value of 15.7 nM PMC7459198
Murine primary lung fibroblasts ≥ 30 nM 48 hours To evaluate the effect of GSK461364 on lung fibroblast proliferation, results showed that GSK461364 significantly suppressed lung fibroblast proliferation. PMC10236721
Murine lung epithelial cells ≥ 30 nM 48 hours To evaluate the effect of GSK461364 on lung epithelial cell proliferation, results showed that GSK461364 did not significantly suppress lung epithelial cell proliferation. PMC10236721
HEK293T cells 100 nM 72 hours Small RNA sequencing and qPCR validation were used to assess downstream consequences of PLK1 activity on miR biogenesis, identifying a set of ten miRs (miR-1248, miR-1306-5p, miR-2277-5p, miR-29c-5p, miR-93-3p, miR-152-3p, miR-509-3-5p, miR-511-5p, miR-891a-5p and miR-892a) whose expression levels were statistically significantly downregulated by two pharmacological PLK1 kinase domain inhibitors, RO-5203280 and GSK461364. PMC4941640

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NSCLC xenograft model Intravenous 100 mg/kg Single dose, assessed after 4 hours To evaluate the effect of volasertib on tumor growth in NSCLC xenograft models, results showed that volasertib significantly reduced the size of mesenchymal tumors PMC4818738
Mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 35 mg/day or 70 mg/day once daily for several days To evaluate the therapeutic effect of GSK461364 on pulmonary fibrosis, results showed that GSK461364 attenuated pulmonary fibrosis without significantly affecting body weight and survival rate in mice. PMC10236721

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00536835 Lymphoma, Non-Hodgkin PHASE1 COMPLETED 2009-09-29 GSK Investigational Site, Sutt... More >>on, Surrey, SM2 5PT, United Kingdom|GSK Investigational Site, Belfast, Northern Ireland, BT9 7AB, United Kingdom|GSK Investigational Site, London, W12 0NN, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.20mL

1.84mL

0.92mL

18.40mL

3.68mL

1.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories